Performance Indicators
- Commentary
- Executive summary
- Registrations & timeliness
- Ascertainment
- % Death cert only
- % Zero survival
- Microscopically verified
- Mortality : incidence ratios
- Demographics
- Treatment
- Treatment: surgery
- Treatment: radiotherapy
- Treatment: teletherapy
- Treatment: chemotherapy
- Treatment: other
- Treatment: cohorts
- Treatment: quality of data
- Dataset: breast screening
- Dataset: cervical screening
- Dataset: bowel screening
- Dataset: stage complete
- Dataset: grade complete
Performance Indicators Commentary
The diagnosis year 2020 performance indicators for the registries of the UKIACR are available here.
You can click on the various tabs to view the corresponding comparison tables. You can use the search box above the table to filter it, or click on any column in the table to sort by it (if applicable). Please read the notes under each table, as sometimes the data is not directly comparable.
A detailed commentary of the findings for each registry may be found at this link.
An Excel download of the complete results tables may be found at this link.
Old Performance Indicators Reports
Reports are also available for preceding years. Use the links below to access these reports:
- 2019 data - UKIACR 2021 Report on 2019 data | Commentary
- 2018 data - UKIACR Report 2020 | Commentary
- 2017 data - UKIACR Report 2019 | Commentary
- 2016 data - UKIACR Report 2018 | Commentary
- 2015 data - UKIACR Report 2017 | Commentary
- 2014 data - UKIACR Report 2016 | Commentary
- 2013 data - UKIACR Report 2015 | Commentary
- 2012 data - UKIACR Report 2014 | Commentary
- 2011 data - UKACR Report 2013.xlsx
- 2010 data - UKACR Report 2012.xlsm
- 2009 data - UKACR Report 2011.xlsm
- 2008 data - UKACR Report 2010.xlsm
- 2007 data - UKACR Report 2009.xlsm
- 2006 data - UKACR Report 2008.xlsm
Executive summary
| Target not reached or not in line with other registries |
| Target attained |
| Indicator | Country average (population)1 | Country average (country)1 | England | Scotland | Northern Ireland | Wales |
|---|---|---|---|---|---|---|
| Stability: Percentage change (%) for all cancers (C00-C97 ex. C44) in 2020 compared with 2017-2019 | -10.3% | -10.1% | -10.2% | -9.7% | -8.0% | -12.6% |
| Registry Creep: Percentage (%) for all cancers (C00-C97 ex. C44) of 2019 registrations (extracted between 04/02/2022 and 06/05/2023) compared with registrations extracted between 22/02/2021 and 06/08/22 6. | 0.3% | -0.1% | 0.6% | -2.9% | 1.0% | 0.8% |
| Staging: Proportion (%) of all cases (C00-C97 ex. C44) with valid known stage registered out of all 2020 registered cancers (C00-C97 ex. C44)2 | 75.1% | 75.8% | 75.5% | 66.4% | 81.2% | 80.0% |
| Average of Core Patient Information Complete: Average percentage (%) of all cancers (C00-C97 ex. C44) registered with demographic information3 | 98.9% | 97.8% | 99.3% | 98.3% | 100.0% | 93.5% |
| Average of Core Tumour Information Complete: Average percentage (%) of all cancers (C00-C97 ex. C44) registered with tumour information4 | 96.4% | 96.3% | 96.5% | 96.1% | 96.3% | 96.1% |
| Diagnosing Hospital Known: Percentage (%) of all cancers (C00-C97 ex. C44) registered with an organisation of diagnosis | 96.8% | 96.8% | 96.8% | 95.5% | - | 98.1% |
| Death Certificate Only (DCO) Rates: Percentage (%) of all cancers (C00-C97 ex. C44) registered as a DCO5 | 2.1% | 1.2% | 2.3% | 0.6% | 0.9% | 0.9% |
| Zero Day Survivors: Percentage (%) of all cancers (C00-C97 ex. C44) registered with the date of death equals the date of diagnosis5 | 2.8% | 1.7% | 3.1% | 1.2% | 1.1% | 1.7% |
| Microscopically Verified: Percentage (%) of all cancers (C00-C97 ex. C44) that are microscopically verified | 81.0% | 80.8% | 81.2% | 79.2% | 83.4% | 79.6% |
| Non Specific Codes: Percentage (%) of all cancers (C00-C97 ex. C44) that are microscopically verified with non specific morphology codes | 1.4% | 1.1% | 1.5% | 0.9% | 1.2% | 0.9% |
| Grade: Percentage (%) of all cancers (C00-C97 ex. C44) registered with a known grade | 56.1% | 57.3% | 55.9% | 57.3% | 59.6% | 56.5% |
| Treatment: Percentage (%) of all cancers (C00-C97 ex. C44) registered with any treatment | 85.4% | 82.0% | 85.9% | 86.1% | 74.8% | 81.2% |
| Breast Screening Data: Percentage of breast cancer (C50) cases from 2019 screen detected for ages 50-64 | 50.5% | 51.4% | 50.3% | 50.4% | 49.7% | 55.1% |
| Cervical Screening Data: Percentage of cervical cancer (C53) cases from 2019 screen detected for ages 25-60 | 20.4% | 44.2% | 13.5% | 54.3% | 63.1% | 45.9% |
| Bowel Screening Data: Percentage of bowel cancer (C18-C20) cases from 2019 screen detected for ages 60-69 | 5.8% | 22.1% | 0.0% | 37.1% | 26.6% | 24.9% |
- For England, Scotland, Wales and Northern Ireland.
- Staging target: > 70%
- Core Patient information includes name, address, postcode, sex, date of birth, ethnicity, date of death, unique health identifier
- Core Tumour information includes date of diagnosis, site of primary growth, type of growth, behaviour of growth, basis of diagnosis
- DCO and zero survivor rate targets: <2%
- Extraction dates for last years indicators: England 04/09/2021, Scotland 22/02/2021, Northern Ireland 16/09/2021 & Wales 06/08/2022
Extraction dates for this years indicators: England 01/10/2022, Scotland 04/02/2022, Northern Ireland 09/02/2023, Wales 06/05/2023
Notation '-' denotes not available (average excludes corresponding country)
For England, 0.0% reflects the unavailability of screening data to NCRAS. NCRAS continued to work with the screening programme to try and obtain an extract to use to pilot a new method of loading screening data files on the Encore ‘waterfall’
Registrations and Timeliness
| UKIACR average (population) | UKIACR average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| 2017 | 373685 | 93421 | 311552 | 33080 | 9861 | 19192 |
| 2018 | 389608 | 97402 | 324342 | 34800 | 10066 | 20400 |
| 2019 | 392977 | 98244 | 329185 | 33154 | 10298 | 20340 |
| 2019 (from Previous PI) | 391667 | 97917 | 327173 | 34132 | 10193 | 20169 |
| No. of 2020 not-finalised cases | 206 | 52 | 171 | 31 | 0 | 4 |
| No. of 2020 full cases | 345882 | 86471 | 288753 | 30395 | 9273 | 17461 |
| Registry creep | 0.3% | -0.1% | 0.6% | -2.9% | 1.0% | 0.8% |
| Not-finalised cases | 0.06 | 0.05 | 0.06 | 0.10 | 0.00 | 0.02 |
No. of Cases (current year) and percentage change vs. previous year (persons)
| Statistically significant difference in 2020 compared to 2017-2019 |
| No statistical significant difference in 2020 compared to 2017-2019 |
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| All invasive xnmsc | 345,882 (-10.3%) | -10.1% | 288753 (-10.2%) | 30395 (-9.7%) | 9273 (-8%) | 17461 (-12.6%) |
| All xnmsc 0-24 | 3,582 (-5.1%) | -2.3% | 3043 (-5.5%) | 259 (-9.2%) | 108 (-5%) | 172 (10.5%) |
| All xnmsc 25-59 | 78,872 (-11.7%) | -12.0% | 66157 (-11.7%) | 6870 (-11%) | 2194 (-13.6%) | 3651 (-11.7%) |
| All xnmsc 60-79 | 184,754 (-10.8%) | -10.3% | 153320 (-10.8%) | 16675 (-10.2%) | 5062 (-6.2%) | 9697 (-13.8%) |
| All xnmsc 80+ | 78,674 (-7.6%) | -7.9% | 66233 (-7.4%) | 6591 (-7.1%) | 1909 (-5.8%) | 3941 (-11.2%) |
| All registrations | 539,773 (-14.2%) | -15.7% | 449788 (-13.8%) | 46591 (-15%) | 15505 (-15.1%) | 27889 (-18.9%) |
| Haematology | 30,707 (-9.5%) | -9.6% | 26214 (-9.5%) | 2321 (-9.2%) | 817 (-9.3%) | 1355 (-10.6%) |
| Head and Neck | 12,213 (-4.3%) | -9.3% | 10020 (-3.2%) | 1228 (-5.3%) | 306 (-17.5%) | 659 (-11.1%) |
| Lower GI | 44,420 (-6.6%) | -9.9% | 37315 (-5.2%) | 3632 (-15.7%) | 1176 (-8.1%) | 2297 (-10.7%) |
| Upper GI | 14,875 (-6.6%) | -7.7% | 12271 (-6.4%) | 1434 (-5.7%) | 377 (-7.8%) | 793 (-11%) |
| HPB | 20,396 (2.3%) | 3.4% | 17040 (2.2%) | 1770 (2.7%) | 556 (9.3%) | 1030 (-0.7%) |
| Trachea, Bronchus & Lung | 45,801 (-7%) | -6.8% | 37237 (-6.7%) | 4933 (-8.9%) | 1316 (-3%) | 2315 (-8.3%) |
| Melanoma of skin | 14,741 (-15.9%) | -16.9% | 12477 (-15.8%) | 1183 (-14.5%) | 324 (-18.3%) | 757 (-18.8%) |
| Breast | 48,204 (-15.2%) | -13.3% | 40192 (-15.6%) | 4312 (-11.9%) | 1363 (-9.5%) | 2337 (-16.3%) |
| Cervix | 2,840 (-12.8%) | -15.3% | 2371 (-11.8%) | 266 (-18.2%) | 73 (-12.7%) | 130 (-18.4%) |
| Other Female Genitals | 18,074 (-6%) | -8.8% | 15088 (-5.6%) | 1583 (-5.3%) | 449 (-17%) | 954 (-7.3%) |
| Prostate | 42,895 (-22.1%) | -16.8% | 36016 (-23.1%) | 3394 (-13.7%) | 1224 (-5%) | 2261 (-25.3%) |
| Kidney | 12,397 (-8.9%) | -12.9% | 10444 (-8.1%) | 1058 (-11.5%) | 296 (-21.8%) | 599 (-10.3%) |
| Bladder | 10,250 (-2.1%) | -5.5% | 8752 (-1.4%) | 800 (-2.4%) | 218 (-7.8%) | 480 (-10.6%) |
| Brain and CNS | 5,439 (-5.5%) | -6.1% | 4585 (-5.1%) | 411 (-12.1%) | 149 (-5.3%) | 294 (-1.8%) |
| Thyroid & other endocrine glands | 3,923 (-11.7%) | -15.5% | 3379 (-10.6%) | 274 (-20.1%) | 160 (1.7%) | 110 (-32.9%) |
| CUP | 7,717 (-4.4%) | 0.0% | 6179 (-6%) | 798 (2.1%) | 181 (-0.7%) | 559 (4.7%) |
| Other invasive cancer | 10,990 (-7.2%) | -6.6% | 9173 (-7.6%) | 998 (-4%) | 288 (-10.6%) | 531 (-4.2%) |
| Breast in situ | 5,853 (-30.8%) | -31.7% | 5099 (-30.4%) | 326 (-32.6%) | 194 (-23.4%) | 234 (-40.3%) |
| Cervix in situ | 19,525 (-22.2%) | -33.6% | 16868 (-18.4%) | 1152 (-45.2%) | 594 (-35.7%) | 911 (-35.3%) |
| Other tumours | 44,363 (-17.7%) | -22.6% | 35185 (-15.9%) | 5141 (-21.8%) | 2272 (-22.1%) | 1765 (-30.8%) |
| Other non-melanoma skin cancer | 1984 (-2.8%) | -2.7% | 1647 (-1.9%) | 135 (-22.7%) | 119 (14.1%) | 83 (-0.4%) |
| Basal cell carcinoma | 84241 (-26.8%) | -29.2% | 71364 (-26.1%) | 5827 (-29.1%) | 2036 (-28.3%) | 5014 (-33%) |
| Squamous cell carcinoma | 37925 (-2.6%) | -3.8% | 30872 (-2.7%) | 3615 (1.3%) | 1017 (-10.7%) | 2421 (-3.2%) |
Percentage (%) of death certificate only cases (persons) for 2020
A statistic highlighted in red means that the target was not reached or was not in line with other registries
A statistic highlighted in red means that the target was not reached or was not in line with other registries
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| All invasive xnmsc | 2.1% | 1.2% | 2.3% | 0.6% | 0.9% | 0.9% |
| All xnmsc 0-24 | 0.1% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% |
| All xnmsc 25-59 | 0.3% | 0.1% | 0.3% | 0.1% | 0.0% | 0.1% |
| All xnmsc 60-79 | 1.0% | 0.6% | 1.2% | 0.3% | 0.4% | 0.4% |
| All xnmsc 80+ | 6.4% | 3.9% | 7.1% | 2.0% | 3.5% | 3.0% |
| All registrations | 1.5% | 0.8% | 1.7% | 0.4% | 0.6% | 0.6% |
| Haematology | 2.0% | 1.1% | 2.3% | 0.4% | 0.7% | 0.9% |
| Head and Neck | 0.9% | 0.6% | 1.0% | 0.1% | 1.3% | 0.2% |
| Lower GI | 1.7% | 0.9% | 1.9% | 0.4% | 0.9% | 0.6% |
| Upper GI | 1.9% | 1.3% | 2.0% | 1.2% | 1.1% | 1.0% |
| HPB | 3.8% | 1.5% | 4.5% | 0.6% | 0.4% | 0.5% |
| Trachea, Bronchus & Lung | 2.2% | 1.1% | 2.6% | 0.4% | 0.6% | 0.6% |
| Melanoma of skin | 0.2% | 0.2% | 0.2% | 0.0% | 0.3% | 0.4% |
| Breast | 0.7% | 0.5% | 0.8% | 0.3% | 0.7% | 0.3% |
| Cervix | 0.7% | 0.6% | 0.8% | 0.4% | 1.4% | 0.0% |
| Other Female Genitals | 1.7% | 1.5% | 1.9% | 0.8% | 2.2% | 1.0% |
| Prostate | 1.3% | 0.8% | 1.4% | 0.1% | 0.9% | 0.9% |
| Kidney | 2.0% | 0.7% | 2.3% | 0.1% | 0.0% | 0.5% |
| Bladder | 3.4% | 1.4% | 3.9% | 0.4% | 0.0% | 1.5% |
| Brain and CNS | 3.1% | 1.0% | 3.7% | 0.0% | 0.0% | 0.3% |
| Thyroid & other endocrine glands | 0.7% | 0.4% | 0.7% | 0.0% | 0.0% | 0.9% |
| CUP | 14.0% | 8.2% | 16.2% | 3.0% | 6.6% | 6.8% |
| Other invasive cancer | 4.3% | 4.1% | 4.3% | 5.3% | 3.5% | 3.2% |
| Breast in situ | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cervix in situ | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Other tumours | 1.7% | 0.8% | 2.0% | 0.3% | 0.4% | 0.6% |
Percentage (%) of zero survival cases (persons)
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| All invasive xnmsc | 2.8% | 1.7% | 3.1% | 1.2% | 1.1% | 1.7% |
| All xnmsc 0-24 | 0.3% | 0.4% | 0.3% | 0.4% | 0.9% | 0.0% |
| All xnmsc 25-59 | 0.6% | 0.4% | 0.7% | 0.5% | 0.0% | 0.3% |
| All xnmsc 60-79 | 1.7% | 1.1% | 1.9% | 0.7% | 0.5% | 1.1% |
| All xnmsc 80+ | 7.6% | 4.9% | 8.3% | 3.2% | 3.8% | 4.3% |
| All registrations | 2.0% | 1.2% | 2.2% | 0.8% | 0.7% | 1.1% |
| Haematology | 2.7% | 1.5% | 3.0% | 0.9% | 0.7% | 1.5% |
| Head and Neck | 1.1% | 0.9% | 1.3% | 0.2% | 1.6% | 0.3% |
| Lower GI | 2.5% | 1.5% | 2.7% | 0.9% | 0.9% | 1.4% |
| Upper GI | 3.0% | 2.3% | 3.1% | 1.9% | 1.3% | 2.8% |
| HPB | 5.3% | 2.4% | 6.1% | 1.2% | 0.5% | 1.7% |
| Trachea, Bronchus & Lung | 3.5% | 2.0% | 4.0% | 1.4% | 1.0% | 1.7% |
| Melanoma of skin | 0.3% | 0.2% | 0.3% | 0.0% | 0.3% | 0.4% |
| Breast | 0.8% | 0.6% | 0.9% | 0.4% | 0.7% | 0.4% |
| Cervix | 0.9% | 0.9% | 1.0% | 0.4% | 1.4% | 0.8% |
| Other Female Genitals | 2.2% | 1.8% | 2.3% | 1.2% | 2.2% | 1.4% |
| Prostate | 1.5% | 1.0% | 1.6% | 0.3% | 1.1% | 1.1% |
| Kidney | 2.9% | 1.6% | 3.3% | 0.8% | 0.3% | 1.8% |
| Bladder | 4.1% | 2.0% | 4.6% | 1.4% | 0.0% | 2.1% |
| Brain and CNS | 3.7% | 1.6% | 4.3% | 0.7% | 0.7% | 0.7% |
| Thyroid & other endocrine glands | 1.0% | 0.7% | 1.2% | 0.0% | 0.0% | 1.8% |
| CUP | 16.5% | 10.0% | 18.8% | 6.3% | 5.5% | 9.5% |
| Other invasive cancer | 5.5% | 5.3% | 5.4% | 7.1% | 3.5% | 5.3% |
| Breast in situ | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cervix in situ | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Other tumours | 2.0% | 1.1% | 2.4% | 0.4% | 0.5% | 1.0% |
Percentage (%) of microscopically verified cases (persons)
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| All invasive xnmsc | 81.0% | 80.8% | 81.2% | 79.2% | 83.4% | 79.6% |
| All xnmsc 0-24 | 91.6% | 92.1% | 91.4% | 96.1% | 92.6% | 88.4% |
| All xnmsc 25-59 | 94.9% | 95.7% | 94.7% | 95.7% | 97.1% | 95.2% |
| All xnmsc 60-79 | 85.4% | 85.0% | 85.6% | 83.2% | 87.3% | 83.9% |
| All xnmsc 80+ | 56.3% | 54.8% | 56.9% | 51.1% | 57.1% | 54.2% |
| All registrations | 86.4% | 86.2% | 86.5% | 85.4% | 86.9% | 86.0% |
| Haematology | 83.5% | 88.9% | 82.2% | 92.8% | 92.4% | 88.3% |
| Head and Neck | 96.1% | 96.0% | 96.1% | 96.4% | 95.4% | 96.1% |
| Lower GI | 84.7% | 84.7% | 84.9% | 82.0% | 87.8% | 84.1% |
| Upper GI | 88.7% | 89.0% | 88.8% | 87.7% | 92.8% | 86.8% |
| HPB | 49.2% | 48.2% | 50.1% | 41.0% | 59.2% | 42.4% |
| Trachea, Bronchus & Lung | 63.5% | 62.1% | 64.2% | 58.6% | 62.6% | 62.9% |
| Melanoma of skin | 99.3% | 99.3% | 99.3% | 99.9% | 98.8% | 99.1% |
| Breast | 97.6% | 98.0% | 97.5% | 98.2% | 98.5% | 97.6% |
| Cervix | 97.1% | 97.5% | 97.0% | 98.1% | 98.6% | 96.2% |
| Other Female Genitals | 92.7% | 91.9% | 93.0% | 91.4% | 91.5% | 91.5% |
| Prostate | 82.4% | 82.6% | 82.5% | 81.4% | 83.8% | 82.6% |
| Kidney | 67.2% | 69.4% | 66.6% | 70.4% | 72.3% | 68.1% |
| Bladder | 85.5% | 86.3% | 85.4% | 84.6% | 89.0% | 86.3% |
| Brain and CNS | 63.9% | 58.3% | 65.1% | 66.4% | 55.7% | 45.9% |
| Thyroid & other endocrine glands | 95.8% | 96.2% | 95.6% | 97.1% | 99.4% | 92.7% |
| CUP | 37.6% | 39.1% | 37.6% | 38.3% | 46.4% | 34.0% |
| Other invasive cancer | 82.1% | 79.9% | 83.3% | 72.4% | 86.8% | 77.0% |
| Breast in situ | 99.9% | 100.0% | 99.9% | 100.0% | 100.0% | 100.0% |
| Cervix in situ | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Other tumours | 85.1% | 84.4% | 84.8% | 90.7% | 81.1% | 81.2% |
Percentage (%) of non-specificity of morphology codes for cases which are microscopically verified
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| All xnmsc 0-24 | 1.2% | 0.4% | 1.4% | 0.0% | 0.0% | 0.0% |
| All xnmsc 25-59 | 1.0% | 0.8% | 1.0% | 0.6% | 0.8% | 0.7% |
| All xnmsc 60-79 | 1.2% | 1.0% | 1.3% | 0.8% | 1.2% | 0.8% |
| All xnmsc 80+ | 2.6% | 2.0% | 2.7% | 1.6% | 2.1% | 1.6% |
| All registrations | 1.1% | 0.9% | 1.1% | 0.6% | 1.4% | 0.6% |
| Haematology | 0.5% | 0.4% | 0.5% | 0.4% | 0.3% | 0.5% |
| Head and Neck | 0.9% | 0.8% | 0.9% | 0.9% | 1.4% | 0.2% |
| Lower GI | 1.1% | 0.7% | 1.2% | 0.4% | 0.6% | 0.8% |
| Upper GI | 1.1% | 0.9% | 1.2% | 0.7% | 0.6% | 1.0% |
| HPB | 5.5% | 4.5% | 5.8% | 4.3% | 4.3% | 3.7% |
| Trachea, Bronchus & Lung | 2.3% | 1.7% | 2.5% | 1.6% | 1.6% | 1.2% |
| Melanoma of skin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Breast | 1.2% | 1.2% | 1.2% | 0.5% | 1.9% | 1.1% |
| Cervix | 0.8% | 0.3% | 0.9% | 0.4% | 0.0% | 0.0% |
| Other Female Genitals | 1.0% | 0.5% | 1.2% | 0.6% | 0.0% | 0.1% |
| Prostate | 0.7% | 0.3% | 0.8% | 0.1% | 0.0% | 0.5% |
| Kidney | 1.5% | 0.7% | 1.7% | 0.8% | 0.0% | 0.2% |
| Bladder | 1.0% | 0.7% | 1.1% | 0.3% | 1.0% | 0.5% |
| Brain and CNS | 1.2% | 0.3% | 1.4% | 0.0% | 0.0% | 0.0% |
| Thyroid & other endocrine glands | 1.8% | 1.1% | 2.0% | 0.8% | 0.6% | 1.0% |
| CUP | 15.1% | 15.4% | 15.5% | 13.7% | 23.8% | 8.4% |
| Other invasive cancer | 0.9% | 0.9% | 0.9% | 0.6% | 1.2% | 0.7% |
| Breast in situ | 0.2% | 0.2% | 0.2% | 0.0% | 0.5% | 0.0% |
| Cervix in situ | 1.2% | 0.4% | 1.4% | 0.0% | 0.0% | 0.0% |
| Other tumours | 2.1% | 2.2% | 2.1% | 1.1% | 5.0% | 0.8% |
Mortality : Incidence ratios (2020)
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| All invasive xnmsc | 0.48 | 0.50 | 0.48 | 0.53 | 0.49 | 0.52 |
| All xnmsc 0-24 | 0.12 | 0.12 | 0.12 | 0.13 | 0.12 | 0.10 |
| All xnmsc 25-59 | 0.25 | 0.26 | 0.24 | 0.28 | 0.24 | 0.28 |
| All xnmsc 60-79 | 0.45 | 0.47 | 0.44 | 0.51 | 0.47 | 0.48 |
| All xnmsc 80+ | 0.82 | 0.85 | 0.81 | 0.88 | 0.85 | 0.85 |
| All registrations | 0.32 | 0.33 | 0.31 | 0.36 | 0.30 | 0.34 |
| Haematology | 0.43 | 0.46 | 0.42 | 0.47 | 0.44 | 0.51 |
| Head and Neck | 0.35 | 0.39 | 0.35 | 0.40 | 0.47 | 0.34 |
| Lower GI | 0.41 | 0.43 | 0.40 | 0.50 | 0.37 | 0.44 |
| Upper GI | 0.81 | 0.86 | 0.79 | 0.89 | 0.89 | 0.88 |
| HPB | 0.86 | 0.89 | 0.84 | 0.94 | 0.87 | 0.91 |
| Trachea, Bronchus & Lung | 0.73 | 0.77 | 0.72 | 0.79 | 0.79 | 0.77 |
| Melanoma of skin | 0.16 | 0.17 | 0.16 | 0.15 | 0.18 | 0.18 |
| Breast | 0.24 | 0.24 | 0.24 | 0.23 | 0.23 | 0.27 |
| Cervix | 0.31 | 0.33 | 0.30 | 0.41 | 0.23 | 0.38 |
| Other Female Genitals | 0.41 | 0.45 | 0.40 | 0.46 | 0.48 | 0.44 |
| Prostate | 0.29 | 0.28 | 0.29 | 0.31 | 0.23 | 0.31 |
| Kidney | 0.35 | 0.40 | 0.34 | 0.42 | 0.46 | 0.37 |
| Bladder | 0.55 | 0.58 | 0.54 | 0.58 | 0.59 | 0.61 |
| Brain and CNS | 0.82 | 0.85 | 0.81 | 0.87 | 0.85 | 0.86 |
| Thyroid & other endocrine glands | 0.14 | 0.16 | 0.14 | 0.17 | 0.10 | 0.24 |
| CUP | 1.24 | 1.15 | 1.28 | 1.06 | 1.20 | 1.06 |
| Other invasive cancer | 0.81 | 0.81 | 0.81 | 0.78 | 0.82 | 0.81 |
| Breast in situ | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cervix in situ | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other tumours | 0.09 | 0.08 | 0.10 | 0.07 | 0.05 | 0.12 |
Completeness of the dataset (%) - demographics and diagnostic details
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| Patient's name | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Patient's address | 99.9% | 100.0% | 99.9% | 100.0% | 100.0% | 100.0% |
| Sex | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Ethnicity | 92.2% | 79.3% | 94.9% | 88.1% | - | 54.7% |
| Postcode | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Date of birth | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Unique health identifier | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Anniversary (diagnosis) date | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.9% |
| Site of primary growth | 97.7% | 97.4% | 97.8% | 97.1% | 98.0% | 96.7% |
| Type of growth | 86.0% | 85.0% | 86.3% | 83.9% | 85.0% | 84.8% |
| Behaviour of growth | 99.7% | 99.5% | 99.8% | 99.7% | 98.8% | 99.5% |
| Basis of diagnosis | 98.7% | 99.5% | 98.5% | 100.0% | 99.8% | 99.8% |
| Diagnosis with hospital | 96.8% | 96.8% | 96.8% | 95.5% | - | 98.1% |
% of all cancer cases (xnmsc)
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| Treatment | 85.4% | 82.0% | 85.9% | 86.1% | 74.8% | 81.2% |
| No Treatment | 4.9% | 10.7% | 3.6% | 13.8% | 25.2% | 0.2% |
| Stage I and II patients receiving any treatment (%) | 94.6% | 92.2% | 94.8% | 91.6% | 83.2% | 99.2% |
% of Cases treated with Surgery
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| All invasive xnmsc | 44.8% | 40.3% | 46.2% | 36.3% | 38.6% | 40.1% |
| All xnmsc 0-24 | 48.3% | 45.5% | 48.6% | 47.5% | 30.6% | 55.2% |
| All xnmsc 25-59 | 62.2% | 58.4% | 63.2% | 57.3% | 52.8% | 60.5% |
| All xnmsc 60-79 | 44.9% | 39.5% | 46.6% | 34.8% | 37.7% | 38.8% |
| All xnmsc 80+ | 27.1% | 23.7% | 28.3% | 17.6% | 25.2% | 23.5% |
| Haematology | 5.5% | 3.9% | 5.8% | 3.7% | 0.5% | 5.6% |
| Head and Neck | 49.0% | 42.3% | 51.3% | 37.2% | 39.9% | 41.0% |
| Lower GI | 63.1% | 62.2% | 64.0% | 52.1% | 69.9% | 62.9% |
| Upper GI | 35.8% | 31.1% | 38.7% | 13.2% | 46.2% | 26.2% |
| HPB | 30.2% | 24.5% | 32.8% | 7.5% | 35.8% | 22.0% |
| Trachea, Bronchus & Lung | 24.1% | 15.1% | 26.9% | 12.4% | 9.2% | 12.0% |
| Melanoma of skin | 94.3% | 87.0% | 94.9% | 96.4% | 61.1% | 95.6% |
| Breast | 70.8% | 71.8% | 70.5% | 72.2% | 73.7% | 70.8% |
| Cervix | 57.1% | 45.3% | 60.1% | 42.1% | 32.9% | 46.2% |
| Other Female Genitals | 70.2% | 64.6% | 71.5% | 62.4% | 57.0% | 67.4% |
| Prostate | 18.9% | 12.8% | 20.4% | 12.2% | 6.0% | 12.5% |
| Kidney | 48.2% | 46.7% | 49.2% | 39.5% | 54.7% | 43.6% |
| Bladder | 81.1% | 81.9% | 81.1% | 78.3% | 85.8% | 82.5% |
| Brain and CNS | 45.3% | 42.0% | 45.9% | 48.7% | 37.6% | 36.1% |
| Thyroid & other endocrine glands | 80.6% | 66.3% | 83.7% | 74.5% | 22.5% | 84.5% |
| CUP | 8.4% | 7.0% | 9.5% | 2.3% | 12.7% | 3.6% |
| Other invasive cancer | 53.4% | 46.5% | 55.4% | 42.6% | 41.0% | 47.1% |
| Breast in situ | 82.1% | 83.2% | 81.8% | 86.2% | 83.0% | 81.6% |
| Cervix in situ | 85.5% | 67.1% | 88.1% | 96.4% | 12.8% | 71.4% |
| Other tumours | 58.9% | 52.0% | 60.1% | 67.4% | 21.0% | 59.5% |
| Non-Melanoma Skin Cancer | 47.6% | 55.6% | 44.0% | 90.3% | 44.2% | 44.0% |
% of Cases treated with Radiotherapy
| UKIACR average (population) | UKIACR average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| All invasive xnmsc | 19.3% | 19.9% | 19.4% | 17.8% | 22.5% | 19.7% |
| All xnmsc 0-24 | 15.1% | 15.4% | 15.0% | 17.8% | 14.8% | 14.0% |
| All xnmsc 25-59 | 23.7% | 25.3% | 23.4% | 24.3% | 27.6% | 25.7% |
| All xnmsc 60-79 | 21.2% | 21.6% | 21.3% | 18.7% | 25.2% | 21.2% |
| All xnmsc 80+ | 10.8% | 10.2% | 11.0% | 8.7% | 10.2% | 10.8% |
| Haematology | 9.2% | 7.7% | 9.5% | 8.8% | 4.5% | 7.9% |
| Head and Neck | 58.9% | 58.6% | 59.9% | 46.3% | 61.8% | 66.5% |
| Lower GI | 12.9% | 13.3% | 12.8% | 12.5% | 14.2% | 13.5% |
| Upper GI | 19.0% | 17.7% | 19.7% | 11.2% | 15.4% | 24.3% |
| HPB | 2.7% | 2.4% | 2.8% | 1.4% | 2.5% | 3.1% |
| Trachea, Bronchus & Lung | 25.5% | 26.1% | 25.4% | 25.9% | 29.0% | 24.3% |
| Melanoma of skin | 1.2% | 0.9% | 1.3% | 0.3% | 0.9% | 0.9% |
| Breast | 33.0% | 34.6% | 32.8% | 34.2% | 39.7% | 31.8% |
| Cervix | 42.5% | 49.0% | 41.0% | 49.2% | 58.9% | 46.9% |
| Other Female Genitals | 15.1% | 18.1% | 14.4% | 15.8% | 20.3% | 21.8% |
| Prostate | 17.7% | 16.4% | 18.8% | 6.4% | 26.4% | 14.2% |
| Kidney | 6.5% | 7.3% | 6.4% | 6.9% | 7.8% | 8.0% |
| Bladder | 18.6% | 19.0% | 18.5% | 17.6% | 18.3% | 21.7% |
| Brain and CNS | 45.3% | 45.2% | 45.2% | 45.7% | 42.3% | 47.6% |
| Thyroid & other endocrine glands | 24.6% | 23.0% | 25.2% | 17.2% | 26.3% | 23.6% |
| CUP | 9.4% | 10.5% | 9.2% | 9.4% | 14.4% | 9.1% |
| Other invasive cancer | 14.5% | 15.2% | 14.5% | 12.6% | 17.0% | 16.8% |
| Breast in situ | 26.4% | 30.3% | 25.7% | 31.9% | 43.8% | 19.7% |
| Cervix in situ | 0.0% | 0.1% | 0.0% | 0.0% | 0.3% | 0.0% |
| Other tumours | 1.0% | 0.9% | 1.1% | 0.2% | 1.5% | 0.7% |
| Non-Melanoma Skin Cancer | 1.6% | 1.3% | 1.7% | 0.7% | 1.5% | 1.4% |
% of Cases treated with Teletherapy
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| All invasive xnmsc | 18.1% | 18.4% | 18.2% | 14.9% | 21.5% | 19.1% |
| All xnmsc 0-24 | 11.9% | 11.7% | 12.0% | 10.8% | 14.8% | 9.3% |
| All xnmsc 25-59 | 21.9% | 23.3% | 21.8% | 20.4% | 26.0% | 25.1% |
| All xnmsc 60-79 | 19.9% | 20.1% | 20.1% | 15.7% | 24.0% | 20.5% |
| All xnmsc 80+ | 10.3% | 9.7% | 10.5% | 7.5% | 10.2% | 10.7% |
| Haematology | 8.8% | 7.4% | 9.0% | 8.2% | 4.5% | 7.9% |
| Head and Neck | 57.3% | 55.1% | 59.5% | 32.8% | 61.8% | 66.5% |
| Lower GI | 12.5% | 12.6% | 12.6% | 10.2% | 14.1% | 13.5% |
| Upper GI | 18.2% | 17.1% | 18.9% | 9.9% | 15.4% | 24.3% |
| HPB | 2.1% | 2.2% | 2.2% | 1.2% | 2.2% | 3.1% |
| Trachea, Bronchus & Lung | 25.0% | 25.6% | 25.0% | 24.2% | 29.0% | 24.3% |
| Melanoma of skin | 1.1% | 0.8% | 1.2% | 0.3% | 0.9% | 0.9% |
| Breast | 32.4% | 33.9% | 32.2% | 32.1% | 39.6% | 31.8% |
| Cervix | 40.7% | 41.2% | 40.3% | 42.1% | 35.6% | 46.9% |
| Other Female Genitals | 9.3% | 11.6% | 8.9% | 7.3% | 14.0% | 16.0% |
| Prostate | 16.2% | 14.4% | 17.2% | 4.1% | 22.5% | 13.9% |
| Kidney | 5.6% | 6.9% | 5.4% | 6.6% | 7.8% | 8.0% |
| Bladder | 18.3% | 18.6% | 18.4% | 16.1% | 18.3% | 21.7% |
| Brain and CNS | 43.8% | 41.1% | 44.8% | 30.9% | 42.3% | 46.6% |
| Thyroid & other endocrine glands | 7.3% | 13.2% | 6.5% | 1.8% | 26.3% | 18.2% |
| CUP | 9.0% | 10.0% | 9.0% | 7.5% | 14.4% | 9.1% |
| Other invasive cancer | 10.8% | 11.7% | 10.9% | 7.8% | 17.0% | 10.9% |
| Breast in situ | 26.4% | 30.2% | 25.7% | 31.6% | 43.8% | 19.7% |
| Cervix in situ | 0.0% | 0.1% | 0.0% | 0.0% | 0.3% | 0.0% |
| Other tumours | 0.8% | 0.8% | 0.9% | 0.1% | 1.5% | 0.6% |
| Non-Melanoma Skin Cancer | 1.6% | 1.3% | 1.7% | 0.6% | 1.5% | 1.4% |
% of Cases treated with Chemotherapy
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| All invasive xnmsc | 25.6% | 25.0% | 25.9% | 22.0% | 25.5% | 26.8% |
| All xnmsc 0-24 | 64.9% | 59.5% | 66.1% | 59.8% | 53.7% | 58.1% |
| All xnmsc 25-59 | 40.5% | 41.6% | 40.2% | 39.8% | 41.4% | 45.0% |
| All xnmsc 60-79 | 26.0% | 25.1% | 26.5% | 21.0% | 25.4% | 27.4% |
| All xnmsc 80+ | 7.8% | 6.4% | 8.2% | 4.4% | 6.0% | 7.1% |
| Haematology | 52.2% | 49.6% | 52.6% | 50.7% | 43.9% | 51.2% |
| Head and Neck | 28.7% | 26.7% | 29.3% | 23.5% | 20.6% | 33.4% |
| Lower GI | 30.8% | 31.2% | 31.0% | 26.3% | 34.2% | 33.3% |
| Upper GI | 38.2% | 38.0% | 38.5% | 34.0% | 40.3% | 39.1% |
| HPB | 23.4% | 21.2% | 24.2% | 16.6% | 23.4% | 20.8% |
| Trachea, Bronchus & Lung | 22.4% | 22.0% | 23.1% | 15.0% | 24.2% | 25.7% |
| Melanoma of skin | 3.8% | 3.9% | 3.9% | 0.5% | 4.0% | 7.4% |
| Breast | 32.5% | 32.6% | 32.4% | 31.7% | 31.8% | 34.5% |
| Cervix | 39.6% | 41.5% | 38.9% | 44.7% | 42.5% | 40.0% |
| Other Female Genitals | 29.2% | 27.3% | 29.5% | 29.5% | 24.5% | 25.5% |
| Prostate | 5.6% | 6.2% | 5.6% | 2.2% | 8.2% | 8.9% |
| Kidney | 9.3% | 10.8% | 9.3% | 4.2% | 12.8% | 16.7% |
| Bladder | 26.6% | 27.5% | 26.7% | 22.6% | 28.9% | 31.7% |
| Brain and CNS | 35.0% | 32.1% | 35.5% | 35.3% | 28.2% | 29.6% |
| Thyroid & other endocrine glands | 3.4% | 7.3% | 2.9% | 4.4% | 3.8% | 18.2% |
| CUP | 7.9% | 9.3% | 7.9% | 8.8% | 15.5% | 5.2% |
| Other invasive cancer | 26.5% | 26.1% | 26.6% | 24.7% | 26.7% | 26.4% |
| Breast in situ | 1.7% | 1.8% | 1.7% | 0.3% | 4.6% | 0.4% |
| Cervix in situ | 0.0% | 0.1% | 0.0% | 0.0% | 0.3% | 0.0% |
| Other tumours | 12.2% | 10.2% | 12.5% | 14.1% | 4.4% | 9.9% |
| Non-Melanoma Skin Cancer | 0.2% | 0.5% | 0.1% | 0.9% | 1.0% | 0.1% |
% of Cases for other treatments
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| % of Cases treated with Hormone Therapy | ||||||
| All invasive xnmsc | 12.9% | 14.6% | 12.5% | 16.2% | 18.4% | 11.4% |
| Breast | 39.9% | 50.0% | 36.8% | 64.6% | 67.3% | 31.3% |
| Prostate | 51.6% | 52.7% | 51.4% | 54.7% | 56.4% | 48.3% |
| % of Cases treated with Brachytherapy | ||||||
| All invasive xnmsc | 1.2% | 0.9% | 1.2% | 0.5% | 1.0% | 0.9% |
| Breast | 0.2% | 0.1% | 0.2% | 0.0% | 0.1% | 0.0% |
| Prostate | 1.6% | 1.7% | 1.6% | 0.8% | 3.8% | 0.4% |
| % of Cases treated with Watch & Wait/Active Monitoring | ||||||
| All invasive xnmsc | 8.1% | 6.4% | 8.6% | 4.3% | 4.1% | 8.8% |
| Prostate | 25.9% | 19.2% | 27.5% | 16.8% | 9.2% | 23.5% |
| % of Cases treated with Palliative Care | ||||||
| All invasive xnmsc | 9.3% | 7.2% | 10.1% | 2.6% | 7.8% | 8.2% |
Specific cohorts where treatment completeness data is expected (%)
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| % of children and young adults (0-24 group) with cancer & underwent any treatment | 94.6% | 90.0% | 95.3% | 96.9% | 75.9% | 91.9% |
| % of all stage 1 cancer patients who received any treatment | 93.6% | 90.5% | 94.0% | 91.5% | 78.4% | 98.2% |
| % of men under 60 with prostate cancer & received hormone treatment | 29.8% | 32.4% | 29.5% | 29.6% | 43.8% | 26.6% |
| % of women under 60 with breast cancer & received hormone treatment | 27.0% | 37.4% | 23.8% | 53.3% | 57.3% | 15.2% |
| % of all haematological cancer patients who received any treatment | 80.3% | 76.5% | 80.4% | 88.2% | 61.9% | 75.4% |
Quality of treatment data
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | ||
|---|---|---|---|---|---|---|---|
| Surgery (denominator - all tumours known to be treated with surgery, first recorded surgery for that tumour): | |||||||
| Date of surgery known | 99.7% | 99.9% | 99.7% | 100.0% | 100.0% | 100.0% | |
| Trust / hospital of surgery known | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Type of surgery known (OPCS4 code) | 92.8% | 74.5% | 100.0% | 0.0% | 100.0% | 98.1% | |
| Teletherapy (denominator - all tumours known to be treated with teletherapy , first recorded teletherapy treatment for that tumour): | |||||||
| Date of teletherapy known | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Trust / hospital of teletherapy known | 99.9% | 99.4% | 100.0% | 100.0% | 97.5% | 100.0% | |
| Fractions and dose known | 89.8% | 73.1% | 96.7% | 0.0% | 97.5% | 98.4% | |
| Chemotherapy (denominator - all tumours known to be treated with chemotherapy, first recorded chemotherapy treatment for that tumour): | |||||||
| Date of chemotherapy known | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Trust / hospital of chemotherapy known | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Drug name or regimen known | 75.8% | 46.6% | 86.5% | 0.0% | 100.0% | 0.0% | |
| Radiotherapy (denominator - all tumours known to be treated with radiotherapy, take the first recorded radiotherapy event for that tumour): | |||||||
| Date of radiotherapy known | 100.0% | 99.9% | 100.0% | 100.0% | 99.4% | 100.0% | |
| Trust / hospital of radiotherapy known | 99.9% | 99.0% | 100.0% | 100.0% | 96.0% | 100.0% | |
Breast cancer screening completeness (%)
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| Breast cancer - % screen detected for ages 50-64 (data 2020) | 27.1% | 36.5% | 24.5% | 38.1% | 44.6% | 38.7% |
| Breast cancer - % screen detected for ages 50-64 (last year, 2019) | 50.5% | 51.4% | 50.3% | 50.4% | 49.7% | 55.1% |
| Breast cancer - % with full screening history for ages 50-64 (data 2020) | 74.2% | 78.5% | 71.8% | 99.9% | - | 63.8% |
| Breast cancer - % with full screening history for ages 50-64 (last year, 2019) | 97.6% | 89.9% | 98.9% | 99.9% | - | 70.9% |
Cervical cancer screening completeness (%)
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| Cervical cancer - % screen detected for ages 25-60 (data 2020) | 7.5% | 31.3% | 1.3% | 38.1% | 46.3% | 39.3% |
| Cervical cancer - % screen detected for ages 25-60 (last year, 2019) | 20.4% | 44.2% | 13.5% | 54.3% | 63.1% | 45.9% |
| Cervical cancer - % with full screening history for ages 25-60 (data 2020) | 18.6% | 49.1% | 8.6% | 100.0% | - | 38.9% |
| Cervical cancer - % with full screening history for ages 25-60 (last year, 2019) | 43.1% | 60.7% | 36.0% | 100.0% | - | 45.9% |
Bowel cancer screening completeness (%)
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| Bowel cancer - % screen detected for ages 60-69 (data 2020) | 3.8% | 16.9% | 0.0% | 23.2% | 19.3% | 25.2% |
| Bowel cancer - % screen detected for ages 60-69 (last year, 2019) | 5.8% | 22.1% | 0.0% | 37.1% | 26.6% | 24.9% |
| Bowel cancer - % with full screening history for ages 60-69 (data 2020) | 9.8% | 41.7% | 0.0% | 100.0% | - | 25.1% |
| Bowel cancer - % with full screening history for ages 60-69 (last year, 2019) | 11.6% | 41.7% | 0.0% | 99.8% | - | 25.1% |
Completeness of the dataset (%) - stage complete by cancer site groups summary (persons)
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| All invasive xnmsc | 75.1% | 75.8% | 75.5% | 66.4% | 81.2% | 80.0% |
| Haematology | 54.4% | 46.5% | 58.2% | 0.0% | 54.4% | 73.3% |
| Head and Neck | 84.9% | 87.0% | 85.3% | 75.4% | 94.4% | 92.7% |
| Lower GI | 84.2% | 83.7% | 85.1% | 68.5% | 89.7% | 91.4% |
| Upper GI | 74.0% | 76.5% | 73.5% | 72.5% | 77.2% | 82.7% |
| HPB | 68.4% | 70.9% | 68.2% | 66.4% | 76.9% | 72.1% |
| Bronchus & Lung | 90.7% | 92.3% | 90.2% | 92.0% | 94.4% | 92.5% |
| Melanoma | 85.5% | 80.5% | 88.0% | 54.5% | 86.4% | 93.3% |
| Breast | 86.0% | 88.0% | 85.9% | 84.2% | 96.6% | 85.2% |
| Cervix | 87.9% | 92.3% | 86.9% | 90.6% | 97.3% | 94.6% |
| Other Female Genitals | 80.3% | 82.8% | 80.4% | 71.4% | 91.2% | 88.1% |
| Prostate | 84.2% | 85.8% | 84.1% | 78.4% | 89.7% | 90.9% |
| Bladder | 76.5% | 79.5% | 76.6% | 66.4% | 90.4% | 84.6% |
| Kidney | 78.3% | 83.9% | 77.4% | 79.2% | 93.6% | 85.5% |
| Thyroid and other endocrine glands | 65.8% | 70.4% | 64.8% | 70.4% | 74.3% | 71.9% |
| Non Melanoma skin | 1.4% | 5.0% | 1.5% | 0.0% | 16.8% | 1.5% |
| Brain | 0.6% | 0.3% | 0.7% | 0.0% | 0.0% | 0.7% |
| CUP | 49.5% | 39.6% | 55.7% | 0.0% | 50.0% | 52.6% |
| Other invasive cancer | 54.1% | 45.8% | 57.5% | 23.0% | 46.6% | 56.0% |
Completeness of the dataset (%) - grade complete by cancer site groups summary (persons)
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| All invasive xnmsc | 56.1% | 57.3% | 55.9% | 57.3% | 59.6% | 56.5% |
| All xnmsc 0-24 | 27.7% | 37.4% | 25.2% | 47.5% | 47.2% | 29.7% |
| All xnmsc 25-59 | 65.5% | 67.8% | 64.8% | 69.8% | 69.4% | 67.2% |
| All xnmsc 60-79 | 60.8% | 61.5% | 60.7% | 61.3% | 63.0% | 61.2% |
| All xnmsc 80+ | 37.1% | 37.0% | 37.3% | 34.5% | 40.0% | 36.3% |
| All registrations | 43.8% | 45.3% | 43.3% | 47.3% | 45.5% | 45.1% |
| Haematology | 18.0% | 36.8% | 13.9% | 47.2% | 72.8% | 13.3% |
| Head and Neck | 74.2% | 77.9% | 73.4% | 74.6% | 81.4% | 82.1% |
| Lower GI | 75.8% | 74.8% | 76.0% | 75.4% | 72.9% | 75.0% |
| Upper GI | 72.4% | 73.1% | 72.4% | 71.2% | 76.1% | 72.5% |
| HPB | 27.4% | 23.9% | 28.5% | 20.2% | 24.5% | 22.3% |
| Trachea, Bronchus & Lung | 21.8% | 21.7% | 21.5% | 23.3% | 16.2% | 25.7% |
| Melanoma of skin | 0.4% | 0.3% | 0.4% | 0.7% | 0.0% | 0.1% |
| Breast | 95.5% | 95.7% | 95.4% | 96.2% | 95.8% | 95.2% |
| Cervix | 82.6% | 78.3% | 83.2% | 82.3% | 63.0% | 84.6% |
| Other Female Genitals | 76.0% | 76.4% | 76.1% | 72.4% | 78.4% | 78.8% |
| Prostate | 78.2% | 78.2% | 78.1% | 78.8% | 75.7% | 80.1% |
| Kidney | 53.4% | 53.7% | 53.4% | 52.4% | 55.1% | 53.8% |
| Bladder | 79.6% | 81.9% | 79.3% | 78.0% | 87.2% | 82.9% |
| Brain and CNS | 65.4% | 58.0% | 67.1% | 63.0% | 55.7% | 46.3% |
| Thyroid and other endocrine glands | 18.2% | 16.5% | 18.2% | 28.5% | 3.8% | 15.5% |
| CUP | 19.6% | 17.6% | 19.9% | 19.3% | 12.2% | 19.1% |
| Other invasive cancer | 29.6% | 29.1% | 30.0% | 26.9% | 31.9% | 27.5% |